Introduction to CereSpir
CereSpir is targeting the emerging field of immuno-neurology via a novel mechanism for the treatment of neuroinflammatory and neurodegenerative conditions.
CereSpir Incorporated is a privately held, science-driven pharmaceutical company with an innovative approach to treating neuroinflammatory and neurodegenerative disorders. Our lead compound, itanapraced (CSP-1103), is a small molecule with good oral bioavailability, a long plasma half-life and substantial penetration into the brain. In a Phase 2 study in patients with mild cognitive impairment (MCI) treated up to two years (double blind for 3 months; open label thereafter), it was found to be well tolerated and produced dose-related statistically significant reductions, in the brain, of two key neuroinflammatory mediators, soluble CD40 ligand and TNF-α as well as, total tau, a recognized marker of neurodegeneration. In addition, patients exhibited stable cognitive function throughout the long duration of the trial. Compelling new data from pre-clinical models of two other poorly treated diseases and insights regarding the mechanism of action have led us to a new strategy. We are currently focused on two indications: a) Parkinson’s disease (PD) and b) Acute Isolated Traumatic Brain Injury (aiTBI). CereSpir is leading the way with a novel approach to the treatment of these conditions, firstly, by preventing the accumulation of overactive immune cells in the brain, and, secondly, by protecting nerve cells from overactive stress response mechanisms that lead to cell damage and death. CereSpir has leveraged its science to better understand how these pathways are linked and how they can be modulated through the intracellular domain (AICD) of the amyloid precursor protein (APP) which is increasingly implicated as a critically important signaling protein both in health and disease, affecting multiple pathologies.